Immatics N.V. Share

Immatics N.V. (IMTX) is a clinical-stage biopharmaceutical company focused on the discovery and development of T cell receptor (TCR)-based immunotherapies for the treatment of cancer. The company engineers proprietary adoptive cell therapies and antibody-like TCR bispecifics to target intracellular cancer targets. Immatics' innovative platform aims to overcome the challenges of traditional cancer treatments by redirecting and activating the patient's own immune system to recognize and eliminate tumor cells. The company's research and development efforts are centered on providing novel therapeutic options for patients with advanced and relapsed cancers, addressing significant unmet medical needs in the oncology field. Immatics operates within the biotechnology and pharmaceutical industries, contributing to advancements in immunotherapy and personalized cancer treatment approaches.